CompletedPhase 2NCT00006005

Thalidomide in Treating Patients With Gynecologic Sarcomas

Studying Carcinosarcoma of the corpus uteri

Last synced from ClinicalTrials.gov May 8, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: New York University Cancer Institute
Principal Investigator: Scott Wadler, MD
Weill Medical College of Cornell University
Intervention: thalidomide(drug)
Eligibility: FEMALE
Timeline: 2000 – 2006

Study locations (10)

Cancer Center of Albany Medical Center, Albany, New York, United States
North Shore University Hospital, Manhasset, New York, United States
St. Vincent's Comprehensive Cancer Center, New York, New York, United States
NYU School of Medicine's Kaplan Comprehensive Cancer Center, New York, New York, United States
St. Luke's-Roosevelt Hospital Center - Roosevelt Division, New York, New York, United States
New York Weill Cornell Cancer Center at Cornell University, New York, New York, United States
Mount Sinai School of Medicine, New York, New York, United States
Albert Einstein Clinical Cancer Center, The Bronx, New York, United States
New York Medical College, Valhalla, New York, United States
University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00006005 on ClinicalTrials.gov

Other trials for Carcinosarcoma of the corpus uteri

Additional recruiting or active studies for the same condition.

See all trials for Carcinosarcoma of the corpus uteri →

← Back to all trials